Stay updated on Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to reflect the latest version as v2.16.3, replacing the previous version v2.16.2. The estimated last update posted has been removed.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has updated its study locations, adding several new sites in Berlin, Nashville, Hamilton, and others, while removing multiple locations in Turkey, Korea, Japan, and Mexico. Additionally, the last update date and revision number have been changed.SummaryDifference4%
- Check18 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check25 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check61 days agoChange DetectedThe page has been updated to include new drug information related to Non-Small Cell Lung Cancer (NSCLC) treatments, specifically mentioning Carboplatin, Cisplatin, Tiragolumab, and Pembrolizumab, while significant details about the study's purpose and criteria have been removed.SummaryDifference13%
Stay in the know with updates to Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.